Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06006273 · ClinicalTrials.gov registry record · Phase 1

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

A Phase 1 study of Refractory Solid Tumors, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
48
Enrollment target
1
Study location

NCT06006273: Recruiting Phase 1 study of Refractory Solid Tumors, sponsored by M.D. Anderson Cancer Center.

NCT06006273 is a Phase 1 study of Refractory Solid Tumors that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants, below the 1,460-participant average among 7 other Refractory Solid Tumors trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06006273, a Phase 1 study of Refractory Solid Tumors, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.

Conditions Studied

Refractory Solid Tumors

Interventions

  • DRUG Temozolomide
  • DRUG Irinotecan
  • DRUG Eribulin

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2023-08-16
Est. Completion 2028-12-31
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06006273

The ClinicalTrials.gov registry entry for NCT06006273 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,460-participant average among 7 other Refractory Solid Tumors trials with a reported enrollment target (97% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Refractory Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.

NCT06006273 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06006273 about?

NCT06006273 is a clinical study titled "A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors". To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.

What is the current status of trial NCT06006273?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-08-16. Estimated completion is 2028-12-31.

What conditions does trial NCT06006273 study?

This clinical trial studies the following conditions: Refractory Solid Tumors.

What interventions are being tested in trial NCT06006273?

The interventions under investigation include: Temozolomide (DRUG), Irinotecan (DRUG), Eribulin (DRUG).

Who is sponsoring clinical trial NCT06006273?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06006273 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Solid Tumors

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.